Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
Conditions
Brief summary
This phase II trial studies how well glutaminase inhibitor telaglenastat hydrochloride (CB-839 HCl) works in treating patients with specific genetic mutations and solid tumors or malignant peripheral nerve sheath tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Glutaminase converts an amino acid (building block of proteins) called glutamine to glutamate, which can support several cellular pathways. Telaglenastat hydrochloride works by blocking glutamine activity needed for the growth of cells. When this activity is blocked, the growth of cancer cells may stop and the cancer cells may then die. Cancer is caused by changes (mutations) to genes that control the way cells function and uncontrolled cell growth may result in tumor formation. Specific genetic mutations studied in this clinical trial are NF1 mutation for malignant peripheral nerve sheath tumors, and NF1, KEAP1/NRF2, or STK11/LKB1 mutation for other solid tumors. Telaglenastat hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVE: I. To assess the best overall response rate (BORR) achieved by 6 months of telaglenastat (CB-839) hydrochloride (HCl) treatment in specific pathway aberrant tumors (MPNST, NF1, KEAP1/NRF2 & STK11/ LKB1). SECONDARY OBJECTIVES: I. To determine the safety, progression-free survival (PFS), time to progression (TTP) and overall survival (OS). II. To determine the overall response rate (ORR) (highest objective response achieved between start of therapy and progression), time to response (TTR) and clinical benefit rate (CBR) of telaglenastat (CB-839)HCl. III. To assess pharmacodynamic changes and adaptive responses and correlate with response to treatment as well as disease progression (correlative objective). EXPLORATORY OBJECTIVES: I. Correlate fludeoxyglucose F-18 (18-F FDG) positron emission tomography (PET)/computed tomography (CT) pre-therapy and 8-weeks post-therapy response to telaglenastat (CB-839) HCl therapy. II. Evaluate changes in level of circulating tumor deoxyribonucleic acid (DNA) at baseline, one month on-treatment and time of progression (Molecular Characterization Laboratory \[MoCHA Labs\]) to treatment response. III. Quantify the peripheral blood concentrations of the metabolites: aspartate, glutamate, glutamine and arginine (@Mayo clinic Oncometabolomics core) and correlate with response. IV. Evaluate the pharmacodynamic (PD) effect of telaglenastat (CB-839) HCl on systemic levels of the tricarboxylic acid (TCA) cycle metabolites in peripheral blood (baseline and one month) as part of the protocol. V. Evaluate tumor by reverse phase protein array (@core facility at MD Anderson) and ribonucleic acid (RNA) sequencing (seq) to evaluate changes from pre-treatment, during treatment and post treatment specimens. VI. Perform patient-derived tumor xenograft (PDX) modelling-co-clinical trials (@Dr. Funda Meric-Bernstam's lab MD Anderson) to understand response/resistance mechanisms and also evaluate combination therapies for future development. OUTLINE: Patients receive telaglenastat hydrochloride orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, magnetic resonance imaging (MRI), or PET/CT during screening and on study, and collection of blood samples during screening and on study. After completion of study treatment, patients are followed up every 3 months thereafter.
Interventions
PROCEDUREBiospecimen Collection
Undergo collection of blood
PROCEDUREComputed Tomography
Undergo CT or PET/CT
PROCEDUREMagnetic Resonance Imaging
Undergo MRI
Correlative studies
PROCEDUREPositron Emission Tomography
Undergo PET/CT
Given PO
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed malignancy that is metastatic or unresectable * Patient must have histopathologic confirmation of advanced solid tumor with NF1 mutation, NF1 mutant MPNST, KEAP1/NRF2 mutant and STK11/LKB1 mutant tumors (molecular profiling performed in any Clinical Laboratory Improvement Act \[CLIA\] certified lab \[including tumor and circulating cell-free (cf)DNA\], e.g. Caris, FoundationOne, FoundationAct, Oncomine, Guardant etc.) * NOTE: For all cohorts annotation for actionability will be performed by the PRECISION ONCOLOGY DECISION SUPPORT (PODS) TEAM SHEIKH KHALIFA BIN ZAYED AL NAHYAN INSTITUTE FOR PERSONALIZED CANCER THERAPY (IPCT) THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 6565 MD ANDERSON BLVD, HOUSTON, TX 77030 * Patient must have no standard therapies available * Patient must be aged greater than 18 years old for all cohorts * Patients for NF1 mutant MPNST and NF1 mutant non-MPNST cohorts must be \>= 40 kg * Patient must be at least 4 weeks since any prior surgery or radiotherapy * Females of childbearing potential must have a negative serum pregnancy test (=\< 14 days) prior to start of trial treatment * Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease and biopsiable targetable lesion * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \>= 20 mm (\>= 2 cm) by chest x-ray or as \>= 10 mm (\>= 1 cm) with CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam * Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after central nervous system (CNS)-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during the screening period * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,000/mcL * Platelets \>= 100,000/mcL * Total bilirubin =\< 1.5 x institutional upper limit of normal (ULN) and up to 3 ml/dL for patients with Gilbert's disease * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 x institutional ULN and =\< 5 x institutional ULN for patients with liver metastases * Creatinine =\< institutional ULN, as age appropriate OR * Glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * The effects of telaglenastat (CB-839) HCl on the developing human fetus are unknown. For this reason and because anti-metabolic agents like telaglenastat (CB-839) HCl are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of telaglenastat (CB-839) HCl administration * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study * Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1) * Patients who are receiving any other investigational agents * History of allergic reactions attributed to compounds of similar chemical or biologic composition to telaglenastat (CB-839) HCl * Patients with glioma will be excluded * Patients with active or prior history of hepatitis B or C will be excluded * Telaglenastat (CB-839) HCl is a weak in vitro inhibitor of CYP2C9. Therefore, patients receiving any medications or substances that are substrates of CYP2C9 are eligible, but should use caution with substrates that have a narrow therapeutic index. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study because telaglenastat (CB-839) HCl is anti-metabolic agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with telaglenastat (CB-839) HCl, breastfeeding should be discontinued if the mother is treated with telaglenastat (CB-839) HCl
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best Overall Response Rate by 6 Months | Up to 6 months from treatment start date | Best overall response rate (BORR) based on RECIST V1.1 achieved by 6 months of CB-839 HCl treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Progression | Time to progression starting at C1D1, assessed up to 2 years from treatment start date | Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death. |
| Overall Survival | Time to death from any cause, assessed up to 2 years from treatment start date | Will estimate using the Kaplan-Meier method with time zero set to C1D1. Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death. |
| Overall Response Rate | From start of treatment until disease progression/recurrence, assessed up to 2 years | — |
| Clinical Benefit Rate | Up to 2 years from treatment start date | — |
| Incidence of Adverse Events | Up to 2 years from treatment start date | Will be assessed by Common Terminology Criteria for Adverse Events version 5.0. Will tabulate toxicity by cohort, type, severity and attribution. |
| Progression-free Survival | Time to progression or death whichever comes first, assessed up to 2 years from treatment start date | Will estimate using the Kaplan-Meier method with time zero set to cycle 1, day 1 (C1D1). Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death. |
Other
| Measure | Time frame | Description |
|---|---|---|
| PD Tumor Oncometabolite Levels of Aspartate | Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose | Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis. |
| Pharmacodynamic (PD) Tumor Oncometabolite Levels of Glutamine | Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose | Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis. |
| PD Tumor Oncometabolite Levels of Glutamate | Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose | Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis. |
Countries
United States
Participant flow
Pre-assignment details
Out of the 55 patients enrolled, one patient did not receive treatment due to a death before starting the trial.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 NF1 mutant malignant peripheral nerve sheath tumors (MPNST) | 9 |
| Cohort 2 NF1 mutant other cancers | 26 |
| Cohort 3 KEAP1/NRF2 mutant cancers | 9 |
| Cohort 4 STK11/LKB1 mutant cancers | 10 |
| Total | 54 |
Baseline characteristics
| Characteristic | Cohort 3 | Cohort 4 | Total | Cohort 1 | Cohort 2 |
|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 2 Participants | 2 Participants | 20 Participants | 2 Participants | 14 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants | 8 Participants | 34 Participants | 7 Participants | 12 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 9 Participants | 9 Participants | 52 Participants | 8 Participants | 26 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 2 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 9 Participants | 5 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 7 Participants | 7 Participants | 42 Participants | 4 Participants | 24 Participants |
| Region of Enrollment United States | 9 participants | 10 participants | 54 participants | 9 participants | 26 participants |
| Sex: Female, Male Female | 4 Participants | 5 Participants | 30 Participants | 4 Participants | 17 Participants |
| Sex: Female, Male Male | 5 Participants | 5 Participants | 24 Participants | 5 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 7 / 9 | 20 / 26 | 6 / 9 | 8 / 10 |
| other Total, other adverse events | 9 / 9 | 24 / 26 | 8 / 9 | 10 / 10 |
| serious Total, serious adverse events | 5 / 9 | 7 / 26 | 4 / 9 | 6 / 10 |
Outcome results
Primary
Best Overall Response Rate by 6 Months
Best overall response rate (BORR) based on RECIST V1.1 achieved by 6 months of CB-839 HCl treatment
Time frame: Up to 6 months from treatment start date
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | Best Overall Response Rate by 6 Months | Complete Response (CR)/Partial response (PR) | 0 Participants |
| Cohort 1 | Best Overall Response Rate by 6 Months | Stable Disease (SD) | 4 Participants |
| Cohort 1 | Best Overall Response Rate by 6 Months | Progressive disease (PD) | 4 Participants |
| Cohort 1 | Best Overall Response Rate by 6 Months | Treatment Failure | 1 Participants |
| Cohort 2 | Best Overall Response Rate by 6 Months | Stable Disease (SD) | 10 Participants |
| Cohort 2 | Best Overall Response Rate by 6 Months | Progressive disease (PD) | 14 Participants |
| Cohort 2 | Best Overall Response Rate by 6 Months | Treatment Failure | 1 Participants |
| Cohort 2 | Best Overall Response Rate by 6 Months | Complete Response (CR)/Partial response (PR) | 1 Participants |
| Cohort 3 | Best Overall Response Rate by 6 Months | Progressive disease (PD) | 6 Participants |
| Cohort 3 | Best Overall Response Rate by 6 Months | Stable Disease (SD) | 2 Participants |
| Cohort 3 | Best Overall Response Rate by 6 Months | Treatment Failure | 1 Participants |
| Cohort 3 | Best Overall Response Rate by 6 Months | Complete Response (CR)/Partial response (PR) | 0 Participants |
| Cohort 4 | Best Overall Response Rate by 6 Months | Treatment Failure | 1 Participants |
| Cohort 4 | Best Overall Response Rate by 6 Months | Stable Disease (SD) | 4 Participants |
| Cohort 4 | Best Overall Response Rate by 6 Months | Complete Response (CR)/Partial response (PR) | 0 Participants |
| Cohort 4 | Best Overall Response Rate by 6 Months | Progressive disease (PD) | 5 Participants |
Secondary
Clinical Benefit Rate
Time frame: Up to 2 years from treatment start date
Secondary
Incidence of Adverse Events
Will be assessed by Common Terminology Criteria for Adverse Events version 5.0. Will tabulate toxicity by cohort, type, severity and attribution.
Time frame: Up to 2 years from treatment start date
Secondary
Overall Response Rate
Time frame: From start of treatment until disease progression/recurrence, assessed up to 2 years
Secondary
Overall Survival
Will estimate using the Kaplan-Meier method with time zero set to C1D1. Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.
Time frame: Time to death from any cause, assessed up to 2 years from treatment start date
Secondary
Progression-free Survival
Will estimate using the Kaplan-Meier method with time zero set to cycle 1, day 1 (C1D1). Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.
Time frame: Time to progression or death whichever comes first, assessed up to 2 years from treatment start date
Secondary
Time to Progression
Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.
Time frame: Time to progression starting at C1D1, assessed up to 2 years from treatment start date
Other Pre-specified
PD Tumor Oncometabolite Levels of Aspartate
Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.
Time frame: Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose
Other Pre-specified
PD Tumor Oncometabolite Levels of Glutamate
Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.
Time frame: Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose
Other Pre-specified
Pharmacodynamic (PD) Tumor Oncometabolite Levels of Glutamine
Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.
Time frame: Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose